Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled, Phase II Trial Comparing Sintilimab and Pembrolizumab at First-line Setting in Patients With Advanced Non-small Cell Lung Cancer

Next Previous
Search
Trial Profile

A Randomized Controlled, Phase II Trial Comparing Sintilimab and Pembrolizumab at First-line Setting in Patients With Advanced Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Antineoplastics; Pembrolizumab
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Sep 2023 Results of final analysis (at data cutoff date of October 31 2022, ), presented at the 24th World Conference on Lung Cancer
    • 09 Aug 2022 Results (n=68; From Mar. 2020 to Jan. 2022) assessing efficacy and safety of sintilimab versus pembrolizumab as monotherapy or in combination with chemotherapy for treatment naive metastatic non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
    • 07 Jun 2022 Planned number of patients changed from 20 to 68, as per presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top